21,148 Shares in CareDx, Inc. (NASDAQ:CDNA) Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC bought a new position in shares of CareDx, Inc. (NASDAQ:CDNA) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,148 shares of the company’s stock, valued at approximately $375,000.

A number of other hedge funds have also recently bought and sold shares of CDNA. Sterling Capital Management LLC boosted its position in CareDx by 771.2% during the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock worth $27,000 after acquiring an additional 1,126 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in CareDx by 553.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company’s stock worth $84,000 after purchasing an additional 3,322 shares during the period. State of Wyoming purchased a new position in CareDx during the fourth quarter worth approximately $91,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in CareDx by 41.5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company’s stock worth $200,000 after purchasing an additional 2,742 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in CareDx during the fourth quarter worth approximately $208,000.

Insider Buying and Selling at CareDx

In other news, Director Peter Maag sold 13,281 shares of the firm’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the transaction, the director owned 316,743 shares of the company’s stock, valued at approximately $5,457,481.89. This trade represents a 4.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director William A. Hagstrom sold 30,000 shares of the firm’s stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $17.45, for a total transaction of $523,500.00. Following the completion of the transaction, the director directly owned 53,979 shares in the company, valued at approximately $941,933.55. This represents a 35.72% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 129,343 shares of company stock worth $2,238,811. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

CDNA has been the topic of a number of recent analyst reports. Stephens reaffirmed an “overweight” rating and set a $40.00 price target on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. The Goldman Sachs Group cut their price target on shares of CareDx from $34.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, April 17th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $25.00 price target on shares of CareDx in a research note on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.33.

CareDx Trading Down 1.5%

Shares of CDNA stock opened at $19.20 on Friday. The company’s fifty day simple moving average is $17.78 and its 200-day simple moving average is $19.74. CareDx, Inc. has a 52 week low of $14.09 and a 52 week high of $34.84. The company has a market cap of $1.07 billion, a PE ratio of 16.69 and a beta of 2.19.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The business had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. During the same quarter last year, the firm posted ($0.03) EPS. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. Equities research analysts expect that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.